A Oral Formulation Study

Screening ($N = 628$)

Run-in/Transition phase
8 weeks ($n = 530$)

Stabilisation phase
6 weeks ($n = 312$)

98 Screen Failures

183 Dropouts

49 Dropouts

Double-blind phase$^a$ ($n = 205$)

Placebo ($n = 101$)

42 completed
52 relapsed
7 dropped out$^b$

Oral atypical antipsychotic ($n = 104$)

61 completed
23 relapsed
20 dropped out$^c$

B Long-acting Injectable Formulation Study

Screening ($N = 951$)

Run-in/Transition phase
9 weeks ($n = 849$)

Stabilisation phase
24 weeks ($n = 681$)

102 Screen Failures

168 Dropouts

195 Dropouts

Double-blind phase$^a$ ($n = 385$)

Placebo ($n = 192$)

75 completed
90 relapsed
27 dropped out$^d$

Long-acting injectable antipsychotic ($n = 193$)

132 completed
32 relapsed
29 dropped out$^e$